Drug Trial Radar · NCT02604433
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
Last checked: Nov 20, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
336
Actual
Start
May 2, 2016
Primary completion
Jan 5, 2021
Study completion Jan 5, 2021
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- First posted
- Nov 13, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) plus Best supportive care (BSC) versus placebo plus BSC in adults who require regular red blood cell transfusion due to (β)-thalassemia. The study is divided into the following periods: * Historical Period, * Screening/Run-in Period, * Double-blind Treatment Period (48 weeks), * Double-blind Long-term Treatment Period, (at the investigator's discretion an additional 48 weeks), * Open-Label Phase post unblinding and upon Data Monitoring Committee positive recommendation * Post-treatment Follow-up Period
Conditions
- Erythrocyte Transfusion
- Beta-Thalassemia
Interventions
LuspaterceptDrug
Subjects will start with luspatercept at 1 mg/kg dose level.
PlaceboOther
Placebo, Subcutaneous, every 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved Erythroid Response - Week 13 to Week 24Time frame: Baseline: Day -83 to Day 1; Treatment: Weeks 13 to Week 24
Locations
76 sites in 15 countries. Site status is shown where the registry gives one.
Children's Hospital of Los Angeles
Los Angeles, California
Children's Hospital and Research Center at Oakland
Oakland, California
Ann and Robert H Lurie Childrens Hospital of Chicago
Chicago, Illinois
Boston Children's Hospital
Boston, Massachusetts
Weill Cornell Medical College
New York, New York
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Royal Prince Alfred Hospital
Camperdown, Australia
Prince of Wales Hospital
Randwick, New South Wales, Australia
Mater Hospital Brisbane
South Brisbane, Queensland, Australia
Royal Adelaide Hospital Institute of Medical and Veterinary Science
Adelaide, South Australia, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD
Plovdiv, Bulgaria
Specialized Hospital for Active Treatment of Haematological Diseases - Sofia
Sofia, Bulgaria
Multiprofile Hospital for Active Treatment Sveta Marina EAD
Varna, Bulgaria
University Health Network
Toronto, Ontario, Canada
Hopital Henri Mondor
Créteil, France
GH de Institut Catholique St. VincentHématologie
Lille, France
Hopitaux de La Timone
Marseille, France
Hospital of Necker
Paris, France
Laiko General Hospital of Athens
Ampelokipi - Athens, Greece
Local Institution - 405
Ampelokipi - Athens, Greece
General Children's Hospital "Agia Sophia"
Athens, Greece
General Hospital Georgios Gennimatas of Athens
Athens, Greece
University General Hospital of Patras
Rio Patras, Greece
Hippokration Hospital
Thessaloniki, Greece
Local Institution - 404
Thessaloniki, Greece
Soroka University Medical Centre
Beersheba, Israel
Rambam Health Corporation
Haifa, Israel
HaEmek Medical Center
Haïfa (Afula), Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Hadassah Medical Center
Jerusalem, Israel
Galilee Medical Center
Nahariya, Israel
Rabin Medical Center
Petah Tikva, Israel
Presidio Ospedaliero Antonio Perrino
Brindisi, Italy
Universita degli Studi di Cagliari - ASL8
Cagliari, Italy
Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna
Ferrara, Italy
Ente Ospedaliero Ospedali Galliera - Centro della Microcitemia e delle Anemie Congenite
Genoa, Italy
Fondazione Ca Granda IRCCS Ospedale Maggiore
Milan, Italy
AORN A Cardarelli
Naples, Italy
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.